Compare NRIM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIM | ALT |
|---|---|---|
| Founded | 1990 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 573.8M |
| IPO Year | 2002 | 2005 |
| Metric | NRIM | ALT |
|---|---|---|
| Price | $25.83 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 99.4K | ★ 4.2M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $255,581,000.00 | $41,000.00 |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | $19.67 | ★ N/A |
| Revenue Growth | 30.43 | ★ 105.00 |
| 52 Week Low | $19.60 | $2.56 |
| 52 Week High | $93.80 | $6.44 |
| Indicator | NRIM | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 54.47 |
| Support Level | $24.78 | $2.80 |
| Resistance Level | $25.47 | $3.32 |
| Average True Range (ATR) | 0.59 | 0.12 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 15.82 | 69.23 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.